An Open-label, Randomized, 2-treatment, 2-period, 2-way Crossover, Single-dose Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies

Inclusion Criteria:

- Has provided signed, written informed consent.

- Male or female, age >=18 years of age at the time of signing the informed consent
form.

- Has histologically or cytologically confirmed diagnosis of a solid tumor malignancy
that is not responsive to standard therapy (ies) or for which there is no approved
therapy.

- Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

- Able to swallow and retain orally administered medication and does not have any
clinically significant gastrointestinal (GI) abnormalities that may alter absorption
such as malabsorption syndrome or major resection of the stomach or bowels.

- All prior treatment-related toxicities must be National Cancer Institute - Common
Toxicity Criteria for Adverse Events (NCI-CTCAE), version 4.0 <=Grade 1 (except
alopecia) at the time of enrollment.

- Has adequate baseline organ function as defined: ANC >=1.2×10^9/liter (L),
hemoglobin>=9 gram (g)/deciliter (dL), Platelets>=75×10^9/L, partial thromboplastin
time (PTT), prothrombin time (PT) and International normalization ratio (INR) <=1.5
times upper limit of normal (ULN), albumin >=2.5 g/dL, total bilirubin <=1.5 times
ULN alanine aminotransferase (ALT) <=2.5 times ULN, Creatinine or calculated
creatinine clearance >=50 milliliter (mL)/minute (min) and left ventricular ejection
fraction (LVEF)>=lower limit of normal (LLN) by echocardiogram (ECHO) or multigated
acquisition scan (MUGA).

- Women of childbearing potential must have a negative serum pregnancy test within 14
days of first dose of study treatment and agree to use effective contraception,
during the study and for 4 months following the last dose of study treatment.

Exclusion Criteria:

- Prior exposure to a mitogen-activated extracellular signal-regulated kinase (MEK)
inhibitor.

- Anti-cancer therapy (e.g., chemotherapy with delayed toxicity, extensive radiation
therapy, immunotherapy, biologic therapy, or major surgery) within 21 days prior to
randomization; chemotherapy regimens without delayed toxicity within 14 days prior to
randomization.

- Female Subjects: Lactating or actively breastfeeding.

- Has participated in a clinical trial and received investigational drug within 30
days, 5 half-lives or twice the duration of the biological effect of the
investigational product (IP), whichever is longer, prior to randomization in this
study.

- Has participated in a study that resulted in or made a donation of blood or blood
products in excess of 500 mL within 56 days of the first dose of study treatment.

- History or presence of hepatic insufficiency (excluding metastatic hepatic
carcinoma).

- History of interstitial lung disease or pneumonitis.

- Known Human Immunodeficiency Virus, Hepatitis B Virus (HBV), or Hepatitis C Virus
(HCV) infection

- Subjects with laboratory evidence of cleared HBV and HCV infection will be permitted.

- Has a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
chemically related to study treatment, or excipients, or to DMSO.

- Currently using a prohibited medication or requires the use of any of the prohibited
medications during the study. Use of anticoagulants such as warfarin is permitted
provided INR must be monitored in accordance with local institutional practice.

- Has a history of another malignancy. Subjects who have been disease-free for 3 years
or subjects with a history of a completely resected non-melanoma skin cancer and/or
subjects with indolent second malignancies are eligible.

- Any serious and/or unstable pre-existing medical disorder (aside from malignancy
exception above), psychiatric disorder, or other conditions that could interfere with
subject's safety, obtaining informed consent or compliance to the study procedures.

- Has a history or current evidence/risk of retinal vein occlusion (RVO) or central
serous retinopathy (CSR).

- Symptomatic or untreated leptomeningeal or brain metastases, or spinal cord
compression.

- Left ventricular ejection fraction (LVEF), as measured by ECHO or MUGA scan, below
the institutional LLN, or if a LLN does not exist at an institution, <50%.

- QT interval corrected for heart rate using the Bazett formula (QTcB) >=480
millisecond (msec).

- History or current evidence of cardiovascular risk including any of the following:
current clinically significant uncontrolled arrhythmias, acute coronary syndromes
(including myocardial infarction and unstable angina), coronary angioplasty, or
stenting within 6 months prior to randomization, current >= Class II congestive heart
failure as defined by New York Heart Association (NYHA), treatment-refractory
hypertension defined as a blood pressure of systolic blood pressure (SBP) >140
millimeters of mercury (mmHg) and/or diastolic blood pressure (DBP) >90 mmHg which
cannot be controlled by anti-hypertensive therapy, has an intra-cardiac defibrillator
or permanent pacemaker and known cardiac metastases.